First Hepatitis C treatment data demonstrating proof of principle with direct-acting antiviral-only therapy published
18 January 2012 | By Bristol-Myers Squibb Company
Full results from a Phase II clinical trial...
List view / Grid view
18 January 2012 | By Bristol-Myers Squibb Company
Full results from a Phase II clinical trial...
13 January 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is commencing a cash tender offer to purchase all outstanding shares of common stock of Inhibitex...
7 January 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger...
15 December 2011 | By
The companies have expanded the strategic partnership formed last year...
2 December 2011 | By Bristol-Myers Squibb Company
Phase II combination study in patients chronically infected with Hepatitis C...
29 November 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
28 November 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ONGLYZA® (saxagliptin)...
13 November 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
8 November 2011 | By Bristol-Myers Squibb Company
Study evaluated daclatasvir as add-on to peginterferon alfa/ribavirin (alfa/RBV)...
7 November 2011 | By Bristol-Myers Squibb Company
ERBITUX now approved for five indications across two tumor types...
3 November 2011 | By Bristol-Myers Squibb Company
Innovative strategic partnership to license and develop investigational oncology compound...
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
26 October 2011 | By AstraZeneca
US FDA has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months...
19 October 2011 | By Amgen
Amgen appoints Anthony Hooper as Executive VP, Global Commercial Operations...